Prism Medico Reports Profit, Plans Strategic Acquisition

Prism Medico and Pharmacy Limited achieved a net profit of Rs. 31.84 lakh for the year ended March 31, 2026, a significant turnaround from a net loss of Rs. 4.87 lakh in the previous fiscal year. Revenue from operations surged to Rs. 244.34 lakh in FY26 from Rs. 63.19 lakh in FY25.

Reader Takeaway: Profitable turnaround; acquisition key, compliance needs improvement.

What just happened

Prism Medico and Pharmacy Limited has announced a net profit of Rs. 31.84 lakh for the financial year ending March 31, 2026. This marks a substantial shift from the Rs. 4.87 lakh net loss reported in the prior financial year. Revenue from operations also saw a significant jump to Rs. 244.34 lakh.

The company is also seeking shareholder approval to alter the purpose of its preferential issue. Instead of establishing its own plant, the funds will now be used to acquire a 71.32% controlling stake in Infuze Well Private Limited (IWPL) for up to Rs. 23 crore.

Why this matters

This financial turnaround indicates improved operational performance for Prism Medico. The strategic acquisition of Infuze Well, which is setting up a large parenteral manufacturing facility, aims to accelerate the company's entry into manufacturing. This move could significantly alter the company's business model from its current trading focus.

The backstory

In March 2026, Prism Medico had approved a preferential issue. The current proposal to vary the objects of this issue reflects a strategic pivot based on the opportunity to acquire a controlling stake in IWPL, which offers a ready-to-use manufacturing setup.

What changes now

If shareholders approve the variation and the acquisition, Infuze Well will become a subsidiary of Prism Medico. This acquisition is expected to provide immediate manufacturing capabilities, bypassing the long gestation period of a greenfield project.

Risks to watch

Multiple compliance lapses were noted in the Secretarial Audit Report for FY26, including delays in submitting financial results and shareholding patterns, and issues with independent director eligibility. The company must address these to ensure smooth operations and investor confidence.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Financial Year 2025-2026: Net Profit of Rs. 31.84 lakh, Revenue from Operations Rs. 244.34 lakh.
• Financial Year 2024-2025: Net Loss of Rs. 4.87 lakh, Revenue from Operations Rs. 63.19 lakh.
• Proposed Acquisition: Up to Rs. 23 crore for a 71.32% stake in Infuze Well Private Limited.

What to track next

Shareholders should closely watch the outcome of the AGM on September 19, 2026, specifically the approval for the variation of objects for the preferential issue and the acquisition of Infuze Well. Improving the company's compliance record will also be a key factor.